1 Market Overview

1.1 Product Overview and Scope of Drugs for Oncology

1.2 Classification of Drugs for Oncology by Type

1.2.1 Overview: Global Drugs for Oncology Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Drugs for Oncology Revenue Market Share by Type in 2020

1.2.3 Chemotherapy

1.2.4 Targeted Therapy

1.2.5 Immunotherapy (Biologic Therapy)

1.2.6 Hormonal Therapy

1.2.7 Others

1.3 Global Drugs for Oncology Market by Application

1.3.1 Overview: Global Drugs for Oncology Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Blood Cancer

1.3.3 Breast Cancer

1.3.4 Gastrointestinal Cancer

1.3.5 Prostate Cancer

1.3.6 Respiratory/Lung Cancer

1.3.7 Others

1.4 Global Drugs for Oncology Market Size & Forecast

1.5 Global Drugs for Oncology Market Size and Forecast by Region

1.5.1 Global Drugs for Oncology Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Drugs for Oncology Market Size by Region, (2016-2021)

1.5.3 North America Drugs for Oncology Market Size and Prospect (2016-2026)

1.5.4 Europe Drugs for Oncology Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Drugs for Oncology Market Size and Prospect (2016-2026)

1.5.6 South America Drugs for Oncology Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Drugs for Oncology Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Drugs for Oncology Market Drivers

1.6.2 Drugs for Oncology Market Restraints

1.6.3 Drugs for Oncology Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Drugs for Oncology Product and Solutions

2.1.4 Roche Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Roche Recent Developments and Future Plans

2.2 Celgene

2.2.1 Celgene Details

2.2.2 Celgene Major Business

2.2.3 Celgene Drugs for Oncology Product and Solutions

2.2.4 Celgene Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Celgene Recent Developments and Future Plans

2.3 Novartis

2.3.1 Novartis Details

2.3.2 Novartis Major Business

2.3.3 Novartis Drugs for Oncology Product and Solutions

2.3.4 Novartis Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Novartis Recent Developments and Future Plans

2.4 Bristol-Myers Squibb

2.4.1 Bristol-Myers Squibb Details

2.4.2 Bristol-Myers Squibb Major Business

2.4.3 Bristol-Myers Squibb Drugs for Oncology Product and Solutions

2.4.4 Bristol-Myers Squibb Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.5 Johnson & Johnson

2.5.1 Johnson & Johnson Details

2.5.2 Johnson & Johnson Major Business

2.5.3 Johnson & Johnson Drugs for Oncology Product and Solutions

2.5.4 Johnson & Johnson Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Johnson & Johnson Recent Developments and Future Plans

2.6 Merck & Co.

2.6.1 Merck & Co. Details

2.6.2 Merck & Co. Major Business

2.6.3 Merck & Co. Drugs for Oncology Product and Solutions

2.6.4 Merck & Co. Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Merck & Co. Recent Developments and Future Plans

2.7 AstraZeneca

2.7.1 AstraZeneca Details

2.7.2 AstraZeneca Major Business

2.7.3 AstraZeneca Drugs for Oncology Product and Solutions

2.7.4 AstraZeneca Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 AstraZeneca Recent Developments and Future Plans

2.8 Pfizer

2.8.1 Pfizer Details

2.8.2 Pfizer Major Business

2.8.3 Pfizer Drugs for Oncology Product and Solutions

2.8.4 Pfizer Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Pfizer Recent Developments and Future Plans

2.9 Amgen

2.9.1 Amgen Details

2.9.2 Amgen Major Business

2.9.3 Amgen Drugs for Oncology Product and Solutions

2.9.4 Amgen Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Amgen Recent Developments and Future Plans

2.10 Eli Lilly

2.10.1 Eli Lilly Details

2.10.2 Eli Lilly Major Business

2.10.3 Eli Lilly Drugs for Oncology Product and Solutions

2.10.4 Eli Lilly Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Eli Lilly Recent Developments and Future Plans

2.11 AbbVie

2.11.1 AbbVie Details

2.11.2 AbbVie Major Business

2.11.3 AbbVie Drugs for Oncology Product and Solutions

2.11.4 AbbVie Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 AbbVie Recent Developments and Future Plans

2.12 Takeda

2.12.1 Takeda Details

2.12.2 Takeda Major Business

2.12.3 Takeda Drugs for Oncology Product and Solutions

2.12.4 Takeda Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Takeda Recent Developments and Future Plans

2.13 Astellas

2.13.1 Astellas Details

2.13.2 Astellas Major Business

2.13.3 Astellas Drugs for Oncology Product and Solutions

2.13.4 Astellas Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Astellas Recent Developments and Future Plans

2.14 Ipsen

2.14.1 Ipsen Details

2.14.2 Ipsen Major Business

2.14.3 Ipsen Drugs for Oncology Product and Solutions

2.14.4 Ipsen Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Ipsen Recent Developments and Future Plans

2.15 Sanofi

2.15.1 Sanofi Details

2.15.2 Sanofi Major Business

2.15.3 Sanofi Drugs for Oncology Product and Solutions

2.15.4 Sanofi Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 Sanofi Recent Developments and Future Plans

2.16 Bayer

2.16.1 Bayer Details

2.16.2 Bayer Major Business

2.16.3 Bayer Drugs for Oncology Product and Solutions

2.16.4 Bayer Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.16.5 Bayer Recent Developments and Future Plans

2.17 Biogen Idec

2.17.1 Biogen Idec Details

2.17.2 Biogen Idec Major Business

2.17.3 Biogen Idec Drugs for Oncology Product and Solutions

2.17.4 Biogen Idec Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.17.5 Biogen Idec Recent Developments and Future Plans

2.18 Teva

2.18.1 Teva Details

2.18.2 Teva Major Business

2.18.3 Teva Drugs for Oncology Product and Solutions

2.18.4 Teva Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.18.5 Teva Recent Developments and Future Plans

2.19 Otsuka

2.19.1 Otsuka Details

2.19.2 Otsuka Major Business

2.19.3 Otsuka Drugs for Oncology Product and Solutions

2.19.4 Otsuka Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.19.5 Otsuka Recent Developments and Future Plans

2.20 Eisai

2.20.1 Eisai Details

2.20.2 Eisai Major Business

2.20.3 Eisai Drugs for Oncology Product and Solutions

2.20.4 Eisai Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.20.5 Eisai Recent Developments and Future Plans

2.21 Merck KGaA

2.21.1 Merck KGaA Details

2.21.2 Merck KGaA Major Business

2.21.3 Merck KGaA Drugs for Oncology Product and Solutions

2.21.4 Merck KGaA Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.21.5 Merck KGaA Recent Developments and Future Plans

2.22 Gilead Sciences

2.22.1 Gilead Sciences Details

2.22.2 Gilead Sciences Major Business

2.22.3 Gilead Sciences Drugs for Oncology Product and Solutions

2.22.4 Gilead Sciences Drugs for Oncology Revenue, Gross Margin and Market Share (2019-2021)

2.22.5 Gilead Sciences Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Drugs for Oncology Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Drugs for Oncology Players Market Share

3.2.2 Top 10 Drugs for Oncology Players Market Share

3.2.3 Market Competition Trend

3.3 Drugs for Oncology Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Drugs for Oncology Revenue and Market Share by Type (2016-2021)

4.2 Global Drugs for Oncology Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Drugs for Oncology Revenue Market Share by Application (2016-2021)

5.2 Drugs for Oncology Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Drugs for Oncology Revenue by Type (2016-2026)

6.2 North America Drugs for Oncology Revenue by Application (2016-2026)

6.3 North America Drugs for Oncology Market Size by Country

6.3.1 North America Drugs for Oncology Revenue by Country (2016-2026)

6.3.2 United States Drugs for Oncology Market Size and Forecast (2016-2026)

6.3.3 Canada Drugs for Oncology Market Size and Forecast (2016-2026)

6.3.4 Mexico Drugs for Oncology Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Drugs for Oncology Revenue by Type (2016-2026)

7.2 Europe Drugs for Oncology Revenue by Application (2016-2026)

7.3 Europe Drugs for Oncology Market Size by Country

7.3.1 Europe Drugs for Oncology Revenue by Country (2016-2026)

7.3.2 Germany Drugs for Oncology Market Size and Forecast (2016-2026)

7.3.3 France Drugs for Oncology Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Drugs for Oncology Market Size and Forecast (2016-2026)

7.3.5 Russia Drugs for Oncology Market Size and Forecast (2016-2026)

7.3.6 Italy Drugs for Oncology Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Drugs for Oncology Revenue by Type (2016-2026)

8.2 Asia-Pacific Drugs for Oncology Revenue by Application (2016-2026)

8.3 Asia-Pacific Drugs for Oncology Market Size by Region

8.3.1 Asia-Pacific Drugs for Oncology Revenue by Region (2016-2026)

8.3.2 China Drugs for Oncology Market Size and Forecast (2016-2026)

8.3.3 Japan Drugs for Oncology Market Size and Forecast (2016-2026)

8.3.4 South Korea Drugs for Oncology Market Size and Forecast (2016-2026)

8.3.5 India Drugs for Oncology Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Drugs for Oncology Market Size and Forecast (2016-2026)

8.3.7 Australia Drugs for Oncology Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Drugs for Oncology Revenue by Type (2016-2026)

9.2 South America Drugs for Oncology Revenue by Application (2016-2026)

9.3 South America Drugs for Oncology Market Size by Country

9.3.1 South America Drugs for Oncology Revenue by Country (2016-2026)

9.3.2 Brazil Drugs for Oncology Market Size and Forecast (2016-2026)

9.3.3 Argentina Drugs for Oncology Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Drugs for Oncology Revenue by Type (2016-2026)

10.2 Middle East & Africa Drugs for Oncology Revenue by Application (2016-2026)

10.3 Middle East & Africa Drugs for Oncology Market Size by Country

10.3.1 Middle East & Africa Drugs for Oncology Revenue by Country (2016-2026)

10.3.2 Turkey Drugs for Oncology Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Drugs for Oncology Market Size and Forecast (2016-2026)

10.3.4 UAE Drugs for Oncology Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Drugs for Oncology Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Drugs for Oncology Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Drugs for Oncology Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Drugs for Oncology Revenue (USD Million) by Region (2016-2021)

Table 5. Global Drugs for Oncology Revenue Market Share by Region (2021-2026)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Drugs for Oncology Product and Solutions

Table 9. Roche Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Celgene Corporate Information, Head Office, and Major Competitors

Table 11. Celgene Major Business

Table 12. Celgene Drugs for Oncology Product and Solutions

Table 13. Celgene Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Novartis Corporate Information, Head Office, and Major Competitors

Table 15. Novartis Major Business

Table 16. Novartis Drugs for Oncology Product and Solutions

Table 17. Novartis Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 19. Bristol-Myers Squibb Major Business

Table 20. Bristol-Myers Squibb Drugs for Oncology Product and Solutions

Table 21. Bristol-Myers Squibb Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 23. Johnson & Johnson Major Business

Table 24. Johnson & Johnson Drugs for Oncology Product and Solutions

Table 25. Johnson & Johnson Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Merck & Co. Corporate Information, Head Office, and Major Competitors

Table 27. Merck & Co. Major Business

Table 28. Merck & Co. Drugs for Oncology Product and Solutions

Table 29. Merck & Co. Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 31. AstraZeneca Major Business

Table 32. AstraZeneca Drugs for Oncology Product and Solutions

Table 33. AstraZeneca Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Pfizer Corporate Information, Head Office, and Major Competitors

Table 35. Pfizer Major Business

Table 36. Pfizer Drugs for Oncology Product and Solutions

Table 37. Pfizer Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Amgen Corporate Information, Head Office, and Major Competitors

Table 39. Amgen Major Business

Table 40. Amgen Drugs for Oncology Product and Solutions

Table 41. Amgen Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 43. Eli Lilly Major Business

Table 44. Eli Lilly Drugs for Oncology Product and Solutions

Table 45. Eli Lilly Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. AbbVie Corporate Information, Head Office, and Major Competitors

Table 47. AbbVie Major Business

Table 48. AbbVie Drugs for Oncology Product and Solutions

Table 49. AbbVie Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Takeda Corporate Information, Head Office, and Major Competitors

Table 51. Takeda Major Business

Table 52. Takeda Drugs for Oncology Product and Solutions

Table 53. Takeda Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Astellas Corporate Information, Head Office, and Major Competitors

Table 55. Astellas Major Business

Table 56. Astellas Drugs for Oncology Product and Solutions

Table 57. Astellas Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Ipsen Corporate Information, Head Office, and Major Competitors

Table 59. Ipsen Major Business

Table 60. Ipsen Drugs for Oncology Product and Solutions

Table 61. Ipsen Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. Sanofi Corporate Information, Head Office, and Major Competitors

Table 63. Sanofi Major Business

Table 64. Sanofi Drugs for Oncology Product and Solutions

Table 65. Sanofi Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Bayer Corporate Information, Head Office, and Major Competitors

Table 67. Bayer Major Business

Table 68. Bayer Drugs for Oncology Product and Solutions

Table 69. Bayer Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 70. Biogen Idec Corporate Information, Head Office, and Major Competitors

Table 71. Biogen Idec Major Business

Table 72. Biogen Idec Drugs for Oncology Product and Solutions

Table 73. Biogen Idec Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 74. Teva Corporate Information, Head Office, and Major Competitors

Table 75. Teva Major Business

Table 76. Teva Drugs for Oncology Product and Solutions

Table 77. Teva Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 78. Otsuka Corporate Information, Head Office, and Major Competitors

Table 79. Otsuka Major Business

Table 80. Otsuka Drugs for Oncology Product and Solutions

Table 81. Otsuka Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 82. Eisai Corporate Information, Head Office, and Major Competitors

Table 83. Eisai Major Business

Table 84. Eisai Drugs for Oncology Product and Solutions

Table 85. Eisai Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 86. Merck KGaA Corporate Information, Head Office, and Major Competitors

Table 87. Merck KGaA Major Business

Table 88. Merck KGaA Drugs for Oncology Product and Solutions

Table 89. Merck KGaA Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 90. Gilead Sciences Corporate Information, Head Office, and Major Competitors

Table 91. Gilead Sciences Major Business

Table 92. Gilead Sciences Drugs for Oncology Product and Solutions

Table 93. Gilead Sciences Drugs for Oncology Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 94. Global Drugs for Oncology Revenue (USD Million) by Players (2019-2021)

Table 95. Global Drugs for Oncology Revenue Share by Players (2019-2021)

Table 96. Breakdown of Drugs for Oncology by Company Type (Tier 1, Tier 2 and Tier 3)

Table 97. Drugs for Oncology Players Head Office, Products and Services Provided

Table 98. Drugs for Oncology Mergers & Acquisitions in the Past Five Years

Table 99. Drugs for Oncology New Entrants and Expansion Plans

Table 100. Global Drugs for Oncology Revenue (USD Million) by Type (2016-2021)

Table 101. Global Drugs for Oncology Revenue Share by Type (2016-2021)

Table 102. Global Drugs for Oncology Revenue Forecast by Type (2021-2026)

Table 103. Global Drugs for Oncology Revenue by Application (2016-2021)

Table 104. Global Drugs for Oncology Revenue Forecast by Application (2021-2026)

Table 105. North America Drugs for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 106. North America Drugs for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 107. North America Drugs for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 108. North America Drugs for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 109. North America Drugs for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 110. North America Drugs for Oncology Revenue by Country (2021-2026) & (USD Million)

Table 111. Europe Drugs for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 112. Europe Drugs for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 113. Europe Drugs for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 114. Europe Drugs for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 115. Europe Drugs for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 116. Europe Drugs for Oncology Revenue by Country (2021-2026) & (USD Million)

Table 117. Asia-Pacific Drugs for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 118. Asia-Pacific Drugs for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 119. Asia-Pacific Drugs for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 120. Asia-Pacific Drugs for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 121. Asia-Pacific Drugs for Oncology Revenue by Region (2016-2021) & (USD Million)

Table 122. Asia-Pacific Drugs for Oncology Revenue by Region (2021-2026) & (USD Million)

Table 123. South America Drugs for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 124. South America Drugs for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 125. South America Drugs for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 126. South America Drugs for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 127. South America Drugs for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 128. South America Drugs for Oncology Revenue by Country (2021-2026) & (USD Million)

Table 129. Middle East & Africa Drugs for Oncology Revenue by Type (2016-2021) & (USD Million)

Table 130. Middle East & Africa Drugs for Oncology Revenue by Type (2021-2026) & (USD Million)

Table 131. Middle East & Africa Drugs for Oncology Revenue by Application (2016-2021) & (USD Million)

Table 132. Middle East & Africa Drugs for Oncology Revenue by Application (2021-2026) & (USD Million)

Table 133. Middle East & Africa Drugs for Oncology Revenue by Country (2016-2021) & (USD Million)

Table 134. Middle East & Africa Drugs for Oncology Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Drugs for Oncology Picture

Figure 2. Global Drugs for Oncology Revenue Market Share by Type in 2020

Figure 3. Chemotherapy

Figure 4. Targeted Therapy

Figure 5. Immunotherapy (Biologic Therapy)

Figure 6. Hormonal Therapy

Figure 7. Others

Figure 8. Drugs for Oncology Revenue Market Share by Application in 2020

Figure 9. Blood Cancer Picture

Figure 10. Breast Cancer Picture

Figure 11. Gastrointestinal Cancer Picture

Figure 12. Prostate Cancer Picture

Figure 13. Respiratory/Lung Cancer Picture

Figure 14. Others Picture

Figure 15. Global Drugs for Oncology Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 16. Global Drugs for Oncology Revenue and Forecast (2016-2026) & (USD Million)

Figure 17. Global Drugs for Oncology Revenue Market Share by Region (2016-2026)

Figure 18. Global Drugs for Oncology Revenue Market Share by Region in 2020

Figure 19. North America Drugs for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Europe Drugs for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. Asia-Pacific Drugs for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. South America Drugs for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 23. Middle East and Africa Drugs for Oncology Revenue (USD Million) and Growth Rate (2016-2026)

Figure 24. Drugs for Oncology Market Drivers

Figure 25. Drugs for Oncology Market Restraints

Figure 26. Drugs for Oncology Market Trends

Figure 27. Roche Recent Developments and Future Plans

Figure 28. Celgene Recent Developments and Future Plans

Figure 29. Novartis Recent Developments and Future Plans

Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans

Figure 31. Johnson & Johnson Recent Developments and Future Plans

Figure 32. Merck & Co. Recent Developments and Future Plans

Figure 33. AstraZeneca Recent Developments and Future Plans

Figure 34. Pfizer Recent Developments and Future Plans

Figure 35. Amgen Recent Developments and Future Plans

Figure 36. Eli Lilly Recent Developments and Future Plans

Figure 37. AbbVie Recent Developments and Future Plans

Figure 38. Takeda Recent Developments and Future Plans

Figure 39. Astellas Recent Developments and Future Plans

Figure 40. Ipsen Recent Developments and Future Plans

Figure 41. Sanofi Recent Developments and Future Plans

Figure 42. Bayer Recent Developments and Future Plans

Figure 43. Biogen Idec Recent Developments and Future Plans

Figure 44. Teva Recent Developments and Future Plans

Figure 45. Otsuka Recent Developments and Future Plans

Figure 46. Eisai Recent Developments and Future Plans

Figure 47. Merck KGaA Recent Developments and Future Plans

Figure 48. Gilead Sciences Recent Developments and Future Plans

Figure 49. Global Drugs for Oncology Revenue Share by Players in 2020

Figure 50. Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 51. Global Top 3 Players Drugs for Oncology Revenue Market Share in 2020

Figure 52. Global Top 10 Players Drugs for Oncology Revenue Market Share in 2020

Figure 53. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 54. Global Drugs for Oncology Revenue Share by Type in 2020

Figure 55. Global Drugs for Oncology Market Share Forecast by Type (2021-2026)

Figure 56. Global Drugs for Oncology Revenue Share by Application in 2020

Figure 57. Global Drugs for Oncology Market Share Forecast by Application (2021-2026)

Figure 58. North America Drugs for Oncology Sales Market Share by Type (2016-2026)

Figure 59. North America Drugs for Oncology Sales Market Share by Application (2016-2026)

Figure 60. North America Drugs for Oncology Revenue Market Share by Country (2016-2026)

Figure 61. United States Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Canada Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Mexico Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. Europe Drugs for Oncology Sales Market Share by Type (2016-2026)

Figure 65. Europe Drugs for Oncology Sales Market Share by Application (2016-2026)

Figure 66. Europe Drugs for Oncology Revenue Market Share by Country (2016-2026)

Figure 67. Germany Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. France Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. United Kingdom Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Russia Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Italy Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. Asia-Pacific Drugs for Oncology Sales Market Share by Type (2016-2026)

Figure 73. Asia-Pacific Drugs for Oncology Sales Market Share by Application (2016-2026)

Figure 74. Asia-Pacific Drugs for Oncology Revenue Market Share by Region (2016-2026)

Figure 75. China Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. Japan Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 77. South Korea Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 78. India Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 79. Southeast Asia Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 80. Australia Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 81. South America Drugs for Oncology Sales Market Share by Type (2016-2026)

Figure 82. South America Drugs for Oncology Sales Market Share by Application (2016-2026)

Figure 83. South America Drugs for Oncology Revenue Market Share by Country (2016-2026)

Figure 84. Brazil Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 85. Argentina Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 86. Middle East and Africa Drugs for Oncology Sales Market Share by Type (2016-2026)

Figure 87. Middle East and Africa Drugs for Oncology Sales Market Share by Application (2016-2026)

Figure 88. Middle East and Africa Drugs for Oncology Revenue Market Share by Country (2016-2026)

Figure 89. Turkey Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 90. Saudi Arabia Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 91. UAE Drugs for Oncology Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 92. Methodology

Figure 93. Research Process and Data Source